


Transforming the future of healthcare by identifying those with highest genetic risk for developing late-onset Alzheimer's Disease

PERFORM EXTENSIVE GENOMIC STUDY ANALYSIS

- Understand your clinical study population using Cytox Polygenic Risk Scoring algorithms
 - Underlying pathway analysis
 - Responders v non-responders
 - Progressors v cognitively stable

Eliminate APOE3 homozygotes least likely to develop AD



ENRICHING TRIAL WITH HIGHEST RISK APOE3 HOMOZYGOTES

- Use Cytox Polygenic Risk Score assessment for identifying APOE3 homozygotes who are at lowest risk to develop AD

RESEARCH


PHASE I/II TRIALS

PHASE III/IV TRIALS

MARKET

SELECT HIGHEST RISK APOE3/E4 SUBJECTS MOST LIKELY TO DEVELOP AD

- In an APOE3/E4 population Cytox Polygenic Risk Score is able to predict onset of AD with an increased accuracy over APOE



DELIVERED GLOBALLY THROUGH A NETWORK OF VALIDATED GENOMIC SERVICE LABS

- Genotyping provided through global network of service labs with deep experience in delivering projects in precision medicine.

AKESQgen

eurofins



NORTH AMERICA

EUROPEAN

ASIA PACIFIC

ThermoFisher
SCIENTIFIC

